Abbott and NIH Join Forces to Advance Neuroscience Research
Abbott Laboratories and the National Institutes of Health have formed an alliance to evaluate applications that could help treat chronic pain and progressive movement disorders, like Parkinson’s disease.
The collaboration is a part of NIH’s BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neuroscience research. The agreement specifically calls for NIH to use the Abbott Park, IL-based company’s neuromodulation technologies for research related to these NIH initiatives to explore their application for chronic p...
Source: MDDI - May 15, 2019 Category: Medical Devices Authors: Omar Ford Tags: R & D Source Type: news
Therapy could improve and prolong sight in those suffering vision loss
(University of California - Berkeley) Ganglion cells in the eye generate noise as the light-sensitive photoreceptors die in diseases such as retinitis pigmentosa. Now, UC Berkeley neurobiologists have found a drug and gene therapy that can tamp down the noise, improving sight in mice with RP. These therapies could potentially extend the period of useful vision in those with degenerative eye diseases, including, perhaps, age-related macular degeneration. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 13, 2019 Category: Biology Source Type: news
Markers for the Study of Diabetic Neuropathy
Widely Used and Frequently PublishedOurPain and Inflammation Research Antibodies have proven valuable for the study of neuropathic, nociceptive and inflammatory pain.This recent publication is focused on Diabetic Neuropathy. Jos é Eduardo Roa-Coria, Jorge Baruch Pineda-Farias, Paulino Barragán-Iglesias, Geovanna Nallely Quiñonez-Bastidas, Ángel Zúñiga-Romero, Juan Carlos Huerta-Cruz, Juan Gerardo Reyes-García, Francisco Javier Flores-Murrieta, Vinicio Granados-SotoView ORCID ID profile and Héctor Isaac Rocha-Gonzál ez (2019).Possible involvement of peripheral TRP channels in the hydrogen sulfide-induced hyper...
Source: Neuromics - January 18, 2019 Category: Neuroscience Tags: Diabetic Neuropathy Hydrogen Sulfide Substance P TRP antibody Source Type: news
UC San Diego Health offers new bluetooth-enabled 'pacemaker' for chronic focal nerve pain
(University of California - San Diego) After living with debilitating phantom leg pain for 18 years, Raul Silva is excited about a new dorsal root ganglion (DRG) stimulation device that erased his pain during a testing phase at UC San Diego Health, one of the only health care providers in the region offering the device. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2018 Category: International Medicine & Public Health Source Type: news
5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein-coupled receptor D
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that is characterized by chronic abdominal pain concurrent with altered bowel habit. Polyunsaturated fatty acid (PUFA) metabolites are increased in abundance in IBS and are implicated in the alteration of sensation to mechanical stimuli, which is defined as visceral hypersensitivity. We sought to quantify PUFA metabolites in patients with IBS and evaluate their role in pain. Quantification of PUFA metabolites by mass spectrometry in colonic biopsies showed an increased abundance of 5-oxoeicosatetraenoic acid (5-oxoETE) only in biopsies taken from patients...
Source: Signal Transduction Knowledge Environment - December 18, 2018 Category: Science Authors: Bautzova, T., Hockley, J. R. F., Perez-Berezo, T., Pujo, J., Tranter, M. M., Desormeaux, C., Barbaro, M. R., Basso, L., Le Faouder, P., Rolland, C., Malapert, P., Moqrich, A., Eutamene, H., Denadai-Souza, A., Vergnolle, N., Smith, E. S. J., Hughes, D. I., Tags: STKE Research Articles Source Type: news
Abbott launches FlexAbility cath ventricular tachycardia ablation trial
Abbott (NYSE:ABT) said yesterday that it launched a study aiming to evaluate ablation treatments for patients with ventricular tachycardia, touting it as the first such trial of its kind.
In the trial, dubbed the Less-VT study, investigators will explore the safety and effectiveness of ablation with the Chicago-area medtech giant’s FlexAbility ablation catheter in treating monomorphic ventricular tachycardia in patients who are unresponsive to drug therapy.
“For some patients with sustained monomorphic ventricular tachycardia, drug therapy is an ineffective treatment option. We want to build a body of clinical...
Source: Mass Device - November 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Featured Abbott Source Type: news
Abbott Nabs Approvals for DRG Invisible Trial System
Abbott Laboratories has nabbed approvals for a chronic pain treatment device that patients can try before getting an implanted version of the technology. The Dorsal Root Ganglion (DRG) Invisible Trial System now has CE mark and a nod from FDA. The Abbott Park, IL-based company said patients who find adequate pain relief with DRG therapy can then have the Proclaim DRG System implanted.
The Proclaim DRG includes an implantable neuromodulator that stimulates the dorsal root ganglion (DRG), an Apple iPad for programming the device, and an iPod touch for the patient control of the device.
“Abbott's DRG Invisib...
Source: MDDI - November 19, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Abbott wins CE Mark, FDA nod for DRG Invisible Trial neuromod system
Abbott (NYSE:ABT) said today that it won FDA clearance and CE Mark approval in the European Union for its DRG Invisible Trial System intended to allow patients with complex chronic pain conditions to receive a trial treatment with the company’s dorsal root ganglion stimulation system.
Abbott’s DRG therapy targets the dorsal root ganglion, a structure adjacent to the spinal cord populated with nerves that transmit chronic pain to the central nervous system. The therapy is intended to aid people living with neuropathic pain conditions by blocking pain signals with electrical pulses transmitted over the DRG, the...
Source: Mass Device - November 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Pain Management Regulatory/Compliance Abbott Source Type: news
New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant
Neurostimulation of the dorsal root ganglion (DRG) can provide pain relief for patients battling chronic pain when previous treatment options were unsuccessful
Abbott's new DRG Invisible Trial System brings an intuitive, wireless approach to the tempora... Devices, Neurology, FDA, Regulatory, Product Launch Abbott, dorsal root ganglion, neurostimulation, DRG Invisible Trial (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2018 Category: Pharmaceuticals Source Type: news
New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant
- Neurostimulation of the dorsal root ganglion (DRG) can provide pain relief for patients battling chronic pain when previous treatment options were unsuccessful (Source: Abbott.com)
Source: Abbott.com - November 15, 2018 Category: Pharmaceuticals Source Type: news
ASA: Dorsal Root Ganglion Stimulation Disrupts Back Pain
FRIDAY, Oct. 19, 2018 -- Dorsal root ganglion (DRG) neurostimulation therapy may reduce pain and disability in patients with chronic lower extremity and back pain, according to a study presented at the annual meeting of the American Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 19, 2018 Category: Pharmaceuticals Source Type: news
Decreased abundance of TRESK two-pore domain potassium channels in sensory neurons underlies the pain associated with bone metastasis
Cancer-associated pain is debilitating. Understanding the mechanisms that cause it can inform drug development that may improve quality of life in patients. Here, we found that the reduced abundance of potassium channels called TRESK in dorsal root ganglion (DRG) neurons sensitized nociceptive sensory neurons and cancer-associated pain. Overexpressing TRESK in DRG neurons suppressed tumor-induced neuronal hyperexcitability and pain hypersensitivity in bone metastasis model rats, whereas knocking down TRESK increased neuronal hyperexcitability and pain hypersensitivity in normal rats. Mechanistically, tumor-associated produ...
Source: Signal Transduction Knowledge Environment - October 16, 2018 Category: Science Authors: Yang, Y., Li, S., Jin, Z.-R., Jing, H.-B., Zhao, H.-Y., Liu, B.-H., Liang, Y.-J., Liu, L.-Y., Cai, J., Wan, Y., Xing, G.-G. Tags: STKE Research Articles Source Type: news
Abbott wins Aetna nod for Proclaim neurostim in chronic pain
Abbott (NYSE:ABT) said today that it won a reimbursement nod from Aetna (NYSE:AET) for its Proclaim dorsal root ganglion neurostimulation therapy for treating chronic pain.
The national coverage decision opens DRG treatment to some 22 million Aetna members, Abbott said. Aetna already covers treatment with Abbott’s spinal cord stimulation devices, the company said. It acquired the neurostim assets when it paid $25 billion for St. Jude Medical back in January 2017.
“Since its launch in the U.S., Abbott’s DRG stimulation has had a profound impact for people living with complex pain conditions. One of the mos...
Source: Mass Device - September 4, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Neuromodulation/Neurostimulation Abbott Reimbursement Source Type: news
Selective inhibition of CaV3.2 channels reverses hyperexcitability of peripheral nociceptors and alleviates postsurgical pain
Pain-sensing sensory neurons of the dorsal root ganglion (DRG) can become sensitized or hyperexcitable in response to surgically induced peripheral tissue injury. We investigated the potential role and molecular mechanisms of nociceptive ion channel dysregulation in acute pain conditions such as those resulting from skin and soft tissue incision. We used selective pharmacology, electrophysiology, and mouse genetics to link increased current densities arising from the CaV3.2 isoform of T-type calcium channels (T-channels) to nociceptive sensitization using a clinically relevant rodent model of skin and deep tissue incision....
Source: Signal Transduction Knowledge Environment - August 28, 2018 Category: Science Authors: Joksimovic, S. L., Joksimovic, S. M., Tesic, V., Garcia-Caballero, A., Feseha, S., Zamponi, G. W., Jevtovic-Todorovic, V., Todorovic, S. M. Tags: STKE Research Articles Source Type: news
UCLA bioengineers show magnetic gel ’s use to ease pain
UCLA bioengineers have demonstrated that a gel-like material containing tiny magnetic particles could be used to manage chronic pain from disease or injury. Broadly, the study demonstrates the promising use of biomechanical forces that push and pull on cells to treat disease.“Much of mainstream modern medicine centers on using pharmaceuticals to make chemical or molecular changes inside the body to treat disease,” said Dino Di Carlo, UCLA professor of bioengineering and the principal investigator of the study. “However, recent breakthroughs in the control of force s at small scales have opened up a new treatment id...
Source: UCLA Newsroom: Health Sciences - August 7, 2018 Category: Universities & Medical Training Source Type: news
